Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients.

Zhang, X; Weeramange, CE; Hughes, BGM; Vasani, S; Liu, ZY; Warkiani, M; Hartel, G; Ladwa, R; Thiery, JP; Kenny, L; Breik, O; Punyadeera, C

Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients.

Zhang, X Weeramange, CE Hughes, BGM Vasani, S Liu, ZY Warkiani, M Hartel, G Ladwa, R Thiery, JP Kenny, L Breik, O Punyadeera, C

Permalink

Publisher:: Springer Nature
Publication Type:: Journal Article
Citation:: Cell Mol Life Sci, 2024, 81, (1), pp. 233
Issue Date:: 2024-05-23

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.8 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Zhang, X
dc.contributor.author	Weeramange, CE
dc.contributor.author	Hughes, BGM
dc.contributor.author	Vasani, S
dc.contributor.author	Liu, ZY
dc.contributor.author	Warkiani, M
dc.contributor.author	Hartel, G
dc.contributor.author	Ladwa, R
dc.contributor.author	Thiery, JP
dc.contributor.author	Kenny, L
dc.contributor.author	Breik, O
dc.contributor.author	Punyadeera, C
dc.date.accessioned	2025-01-28T05:10:24Z
dc.date.available	2024-05-07
dc.date.available	2025-01-28T05:10:24Z
dc.date.issued	2024-05-23
dc.identifier.citation	Cell Mol Life Sci, 2024, 81, (1), pp. 233
dc.identifier.issn	1420-682X
dc.identifier.issn	1420-9071
dc.identifier.uri	http://hdl.handle.net/10453/184285
dc.description.abstract	Patients with head and neck squamous cell carcinoma (HNSCC) are at a high risk of developing recurrence and secondary cancers. This study evaluates the prognostic and surveillance utilities of circulating tumour cells (CTCs) in HNSCC. A total of 154 HNSCC patients were recruited and followed up for 4.5 years. Blood samples were collected at baseline and follow-up. CTCs were isolated using a spiral microfluid device. Recurrence and death due to cancer were assessed during the follow-up period. In patients with HNSCC, the presence of CTCs at baseline was a predictor of recurrence (OR = 8.40, p < 0.0001) and death (OR= ∞, p < 0.0001). Patients with CTCs at baseline had poor survival outcomes (p < 0.0001). Additionally, our study found that patients with CTCs in a follow-up appointment were 2.5 times more likely to experience recurrence or death from HNSCC (p < 0.05) prior to their next clinical visit. Our study highlights the prognostic and monitoring utilities of CTCs' in HNSCC patients. Early identification of CTCs facilitates precise risk assessment, guiding treatment choices and ultimately enhancing patient outcomes.
dc.format	Electronic
dc.language	eng
dc.publisher	Springer Nature
dc.relation.ispartof	Cell Mol Life Sci
dc.relation.isbasedon	10.1007/s00018-024-05269-1
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0601 Biochemistry and Cell Biology, 0606 Physiology, 1103 Clinical Sciences
dc.subject.classification	Biochemistry & Molecular Biology
dc.subject.classification	3101 Biochemistry and cell biology
dc.subject.classification	3205 Medical biochemistry and metabolomics
dc.subject.classification	3211 Oncology and carcinogenesis
dc.subject.mesh	Humans
dc.subject.mesh	Neoplastic Cells, Circulating
dc.subject.mesh	Male
dc.subject.mesh	Head and Neck Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Neoplasm Recurrence, Local
dc.subject.mesh	Squamous Cell Carcinoma of Head and Neck
dc.subject.mesh	Aged
dc.subject.mesh	Carcinoma, Squamous Cell
dc.subject.mesh	Prognosis
dc.subject.mesh	Adult
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Squamous Cell
dc.subject.mesh	Head and Neck Neoplasms
dc.subject.mesh	Neoplasm Recurrence, Local
dc.subject.mesh	Prognosis
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Neoplastic Cells, Circulating
dc.subject.mesh	Squamous Cell Carcinoma of Head and Neck
dc.subject.mesh	Humans
dc.subject.mesh	Neoplastic Cells, Circulating
dc.subject.mesh	Male
dc.subject.mesh	Head and Neck Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Neoplasm Recurrence, Local
dc.subject.mesh	Squamous Cell Carcinoma of Head and Neck
dc.subject.mesh	Aged
dc.subject.mesh	Carcinoma, Squamous Cell
dc.subject.mesh	Prognosis
dc.subject.mesh	Adult
dc.subject.mesh	Follow-Up Studies
dc.title	Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients.
dc.type	Journal Article
utslib.citation.volume	81
utslib.location.activity	Switzerland
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	0606 Physiology
utslib.for	1103 Clinical Sciences
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2025-01-28T05:10:21Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	81
utslib.citation.issue	1

Abstract:

Patients with head and neck squamous cell carcinoma (HNSCC) are at a high risk of developing recurrence and secondary cancers. This study evaluates the prognostic and surveillance utilities of circulating tumour cells (CTCs) in HNSCC. A total of 154 HNSCC patients were recruited and followed up for 4.5 years. Blood samples were collected at baseline and follow-up. CTCs were isolated using a spiral microfluid device. Recurrence and death due to cancer were assessed during the follow-up period. In patients with HNSCC, the presence of CTCs at baseline was a predictor of recurrence (OR = 8.40, p < 0.0001) and death (OR= ∞, p < 0.0001). Patients with CTCs at baseline had poor survival outcomes (p < 0.0001). Additionally, our study found that patients with CTCs in a follow-up appointment were 2.5 times more likely to experience recurrence or death from HNSCC (p < 0.05) prior to their next clinical visit. Our study highlights the prognostic and monitoring utilities of CTCs' in HNSCC patients. Early identification of CTCs facilitates precise risk assessment, guiding treatment choices and ultimately enhancing patient outcomes.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/184285